Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacira Pharm Inc (NQ: PCRX )

57.73 +0.17 (+0.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 269,604
Open 57.60
Bid (Size) 45.00 (2)
Ask (Size) 59.24 (1)
Prev. Close 57.56
Today's Range 57.17 - 58.04
52wk Range 45.05 - 82.16
Shares Outstanding 44,454,792
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Pacira BioSciences' Return On Capital Employed Overview
  
Via Benzinga
Pacira BioSciences: Q2 Earnings Insights
  Pacira BioSciences (NASDAQ:PCRX) reported its Q2 earnings results on Wednesday, August 3, 2022. Here's what investors need to know about the announcement. 
Via Benzinga

Performance

YTD
-5.67%
-5.67%
1 Month
+7.99%
+7.99%
3 Month
-9.14%
-9.14%
6 Month
-10.25%
-10.25%
1 Year
+0.33%
+0.33%

More News

Read More
Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022
From Pacira BioSciences
Via Globe NewsWire
Needham Maintains Buy Rating for Pacira BioSciences: Here's What You Need To Know
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Via Benzinga
Pacira Pharmaceuticals Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark
Via Investor's Business Daily
Regeneron Pharmaceutical Stock Sees RS Rating Jump To 82
Via Investor's Business Daily
Vertex Pharmaceuticals Receives Composite Rating Upgrade
Via Investor's Business Daily
Pacira BioSciences's Return on Invested Capital Overview
Via Benzinga
Gilead Stock Earns Rating Upgrade After Quick Turnaround
Via Investor's Business Daily
Pacira BioSciences: Q1 Earnings Insights
Via Benzinga
Pacira BioSciences Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade
Via Investor's Business Daily
28 Biggest Movers From Yesterday
Via Benzinga
Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92
Via Investor's Business Daily
Stocks That Hit 52-Week Highs On Thursday
Via Benzinga
Biohaven Pharma Holdings Stock Joins Elite Club Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
Via Investor's Business Daily
Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating
Via Investor's Business Daily
Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating
Via Investor's Business Daily
Horizon Therapeutics Stock Shows Market Leadership; Earns 82 RS Rating
Via Investor's Business Daily
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Via Benzinga
Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating
Via Investor's Business Daily
Bear Market Bets In Biotech
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.